Introduction {#S0001}
============

Neural tube defects (NTDs), manifesting as anencephaly or spina bifida, are to some degree preventable developmental malformations \[[@CIT0001]\]. The incidence varies from 1/100 live births in certain regions of China to about 1/5000 live birth in Scandinavian countries\[[@CIT0002]\]. Previous study showed that the rate of NTDs in Gorgan, North of Iran, was 2.88 per 1000 births \[[@CIT0003]\]. Etiology of NTD is considered multifactorial, with genetic, environmental and nutritional factors playing some role\[[@CIT0004], [@CIT0005], [@CIT0006], [@CIT0007], [@CIT0008]\]. Folic acid deficiency may play a role in causation of NTD in the offspring\[[@CIT0009]\].

Some studies have documented lower maternal serum folic acid levels in women with neural tube defects pregnancies in comparison with unaffected pregnancies \[[@CIT0010], [@CIT0011]\]. On the other hand, some studies suggest that nutrients other than folate may also be essential to neural tube closure and have a potential role in risk reduction, with vitamin B~12~ mentioned most often \[[@CIT0011]--[@CIT0015]\]. Vitamin B~12~ is a necessary cofactor for two enzymes in DNA synthesis: folate-- dependent methionine synthesis and folate-- independent methyl malonyl--CoA mutase \[[@CIT0016]\].

Over the last twenty years, evidence for the independent role of B~12~ in NTD development has accumulated from case-control studies on maternal and fetal serum and amniotic fluid B~12~ levels. With two exceptions \[[@CIT0017], [@CIT0018]\], studies on maternal serum B~12~ showed lower levels in mothers who have had NTD--affected pregnancies than in mothers without such a history \[[@CIT0011], [@CIT0014], [@CIT0015], [@CIT0019]--[@CIT0027]\].

Although various studies were done on the role of folate and vitamin B~12~ in different countries, regarding the high prevalence of neural tube defects\[[@CIT0003]\] and the lack of documented studies about the role of maternal serum folic acid and vitamin B~12~ in neural tube defects in this area, we conducted this study to look for an association of maternal folic acid and vitamin B~12~ deficiency and neural tube defects in Gorgan, Northern Iran.

Subjects and Methods {#S0002}
====================

This prospective hospital based case control study was conducted during 2006 at Dezyani Hospital with a labor facility in Gorgan, a capital city in the Golestan province in northern Iran.

This hospital is a referral hospital with an annual rate of more than 6000 deliveries accounting for the largest portion (80%) of deliveries in Gorgan. This study was approved by the Institutional Ethical Committee of Gorgan University of Medical Sciences.

**Sample and study participants:** Twenty three pregnant women whose pregnancies were diagnosed as NTD based on ultrasonographic examination during the 16^th^ week of gestation were recruited as cases. The control group (n=23) consisted of women who were selected among gestational age matched women who had a normal targeted ultrasound during the second trimester (during the 16^th^ wk of gestation) with documented normal fetal outcome. Fetal NTD was suspected, diagnosed with targeted second-trimester ultrasound during the 16^th^ wk of gestation and confirmed with high maternal serum α-fetoprotein levels.

Normal fetus in control (healthy) Mothers were confirmed by ultrasound and maternal serum α-fetoprotein test during the 16^th^ wk of gestation. A peripheral blood sample was collected from mothers in case and control groups after targeted second-trimester ultrasound during the 16^th^ wk of gestation and the serum samples were analyzed for folic acid, B~12~, alpha-fetoprotein, homocysteine level by radioimmunoassay using Gamma counter (Genesis -- USA, and kits from Kavoshyar Company). Serum folate, vitamin B~12~ and homocysteine of less than 5 ng/ml, 160 pg/ml and 5 micromole/liter respectively, were considered as the cut-off value. Also the cut-off level of alpha fetoprotein in sera samples of mothers were considered as \>120 iu/ml.

The diagnosis was evidenced by outcome observation after termination of pregnancy.

**Data collection:** Questionnaire forms were completed with direct interviews with the mothers, carried out by a nurse. Questionnaires given to the mothers included family history, birth place, age, place of residency, as well as mother\'s gynecological and obstetrical history (parity and outcome of pregnancies, preterm and term births, abortions and stillbirths). Any history of congenital malformations was also recorded. Mothers with diabetes mellitus or epilepsy during the first trimester of the pregnancy were excluded from the study.

**Data Analysis:** Categorical data were compared by Chi-square and Fisher\'s exact test. Mann-Whitney U test and independent Student\'s t test were used for comparison of means. Presence of neural tube defect was considered as the dependent factor in multivariable logistics regression analysis.

Independent factors included in the analysis were parity, history of abortions, maternal drug exposure, and folate deficiency as dichotomous variables. Data were analyzed using SPSS 11.5 and STATA SE/8.

Findings {#S0003}
========

The means±SD of Maternal age in case and control group was 24.0±4.6 and 26.5±5 (P=0.08). Number of pregnancy of mothers (mean±SD) in case and control group was 1.6±1 and 2.6±1.5 (P=0.012).91% of Mothers in cases and 57% of Mothers in controls had not history of abortion (P=0.08).91% of mothers in cases and 78% in controls had 20-34 years old ranges.

Serum alpha fetoprotein level (means±SD) in case and controls was 120.2±64.1 and 50±33.5 iu/ml, respectively (P\<0.001). The mean concentration of serum folate did not differ appreciably between cases and controls across the entire study period (8.4 versus 9.3 ng/ml, P=0.97) ([Table 1](#T0001){ref-type="table"}).

###### 

Level of folic acid, B~12~, αFP and homosysteine maternal serum (Mean±SD) in cases and controls

                                       Cases (n=23)   Controls (n=23)   *P*-value
  ------------------------------------ -------------- ----------------- -----------------
  **Folic Acid (ng/ml)**               8.4±4.2        9.3±4.2           t =0.72, 0.79
  **Vitamin B** ~**12**~ **(pg/ml)**   238.7±65.6     227.1±85.5        t =0.514, 0.61
  **αFP (iu/ml)**                      120.2±64.1     50±33.5           t =4.6, \<0.001
  **Homocysteine (micromole/lit)**     8.1±4.5        10.4±4.4          t =1.73, 0.091

αFP: alpha fetoprotein

Overall 30.4% of cases and 13% of the controls in this study had folate deficiency (*P*=0.002). Our findings showed that maternal folate deficiency can increase the probability of a newborn to have NTDs three times more than those of pregnancies with normal folate, although Multivariate logistic regression analysis showed no association between the presence of NTD and folate deficiency (OR=2.9, 95% CI: 0.54-19.8) ([Table 2](#T0002){ref-type="table"}).

###### 

Logistic regression analysis of the variables included in the study

  Risk factor                                 Crude OR (CI 95%)   Adjusted OR (CI 95%)
  ------------------------------------------- ------------------- ----------------------
  **Low levels of serum folic Acid**          2.9 (0.7-13.1)      1.1 (0.11-10.6)
  **Low level of serum vitamin B** ~**12**~   0.7 (0.14-3.6)      1.1 (0.13-9.6)
  **Low level of serum αFP**                  28.6 (3.3-249.7)    28.6 (2.8-296.8)
  **Low level of serum homocysteine**         1.6 (0.24-10.4)     1.3 (0.12-13.1)

OR: Odds Ratio; CI: Confidence Interval; αFP: alpha fetoprotein

The mean concentration of serum B~12~ did not differ between cases and controls in this study (238±65 versus 227± 85 pg/ml, P =0.61) ([Table 1](#T0001){ref-type="table"}).

Overall 13% of cases and 17% of the controls had B~12~ deficiency. Logistic regression analysis showed no Association between the presence of NTD and B~12~ deficiency (OR =0.7, 95% CI: 0.1-4.9) ([Table 2](#T0002){ref-type="table"}).

The mean±SD of serum homocysteine in case and control women was 8.1±4 and 10.4±4 micmol/lit respectively, but this difference was not significant ([Tables 1](#T0001){ref-type="table"} and [2](#T0002){ref-type="table"}).

Discussion {#S0004}
==========

The findings of this study showed that serum folic acid concentration was lower in affected pregnancies compared to control pregnancies, although this difference was not statistically significant. Our findings are similar to pervious studies such as Wald\[[@CIT0010]\], Smithills\[[@CIT0028]\] and Mills\[[@CIT0026]\] ([Table 3](#T0003){ref-type="table"}). Wald et al reported that serum folate level in cases (twenty seven women) was lower than in controls (108 women) but the comparison was not significant \[[@CIT0010]\].

###### 

Summary of findings from previous studies of maternal serum folic acid and NTDs mean differences between cases and controls

  Study                              No of Pregnancies                       Mean ([\*](#TF0001){ref-type="table-fn"} Median) SFA (ng/ml)   Difference   Statistical significance
  ----------------------- ---------- --------------------------------------- -------------------------------------------------------------- ------------ --------------------------
  **Smithells \[26\]**    Affected   5                                       4.9                                                            −1.4         No
  Unaffected              953        6.3                                                                                                                 
  **Mills \[24\]**        Affected   89                                      4.1                                                            −0.2         No
  Unaffected              172        4.3                                                                                                                 
  **Wald \[8\]**          Affected   16                                      4.3[\*](#TF0001){ref-type="table-fn"}                          −1.4         No
  Unaffected              36         5.7[\*](#TF0001){ref-type="table-fn"}                                                                               
  **Economides \[23\]**   Affected   8                                       9.8                                                            2.4          No
  Unaffected              24         7.4                                                                                                                 
  **present study**       Affected   23                                      8.4                                                            −1.1         No
  Unaffected              23         9.3                                                                                                                 

Median of SFA(ng/ml)

On the other hand Bunduki et al\[[@CIT0009]\] in France and Thorand et al\[[@CIT0015]\] in Germany reported that Serum folate level in their cases was significantly lower than in controls.

Also Gaber et al reported that the median serum folate concentrations were similar in cases and controls in Egyptians patients \[[@CIT0029]\].

Given the substantial reduction in risk achievable, it may be surprising that the differences in serum folic acid levels between affected and unaffected pregnancies are too little. An explanation could be that the range of values in a population is relatively narrow; so much of the variation in risk reflects background genetic predisposition rather than folic acid differences. Also geographical, nutritional and biological factors could be involved.

Furthermore, in this study, we did not observe any relation between the serum vitamin B~12~ and NTD. The results of our study are similar to pervious researches\[[@CIT0015], [@CIT0017], [@CIT0018], [@CIT0019], [@CIT0021], [@CIT0025], [@CIT0026]\]. The results of previous studies about the level of B~12~ in NTD pregnancy and healthy pregnancy are depicted in [Table 4](#T0004){ref-type="table"}.

###### 

Summary of findings from previous studies of maternal serum B~12~ and NTDs mean differences between cases and controls

  Study(first author)                             Time of vein puncture      \#Cases/controls   Cases (pg/ml)   Controls (pg/ml)   *P*\<0.05
  ----------------------------------------------- -------------------------- ------------------ --------------- ------------------ -----------
  **Schorah** ^**\[[@CIT0013]\]**^                1^st^ trimester            6/48               309             417                no
  **Molloy** ^**\[[@CIT0016]\]**^                 Early pregnancy            28/363             297             277                no
  **Economides** ^**\[[@CIT0023]\]**^             Mid-trimester              8/24               205             230                no
  **Mills** ^**\[[@CIT0024]\]**^                  1^st^ or 2^nd^ Trimester   78/150             483             520                no
  **Kirke** ^**\[[@CIT0009]\]**^                  Pregnancy                  81/247             243             296                yes
  **Steegers--Theunissen** ^**\[[@CIT0021]\]**^   Pregnancy                  27/31              297             323                no
  **Thorand** ^**\[[@CIT0015]\]**^                Pregnancy                  30/62              256             237                no
  **Stoll** ^**\[[@CIT0019]\]**^                  1^st^ trimester            6/340              430             440                no
  **Present study**                               2^nd^ trimester            23/23              238             227                no

Molloy\[[@CIT0018]\] reported that in early pregnancy no significant differences were found between the affected mothers and the controls in the median values and frequency distributions of vitamin B~12~ concentrations.

Mills study\[[@CIT0026]\] in 89 pregnancies resulting in NTD offspring and 178 control pregnancies showed that in the NTD mothers, the mean±SD level of B~12~ was not significantly lower than in control mothers (482.8±161.1 vs 520.3±191.9 pg/ml) (1.05, 95% CI 0.92 to 1.19). His population-based investigation in a low rate area demonstrated no relationship between maternal vitamin B~12~ level during pregnancy and the risk for NTDs.

Moreover, some studies reported to find an association between maternal serum B~12~ levels and NTD\[[@CIT0019], [@CIT0029], [@CIT0030]\]. A study in Texas-Mexico border population found a strong association between maternal serum B~12~ levels and NTD risk\[[@CIT0017]\]. Also Gaber et al showed that low maternal serum values of vitamin B~12~ can be considered an important etiologic factor for the development of neural tube defects in Egyptian mothers\[[@CIT0029]\].

Zhang\[[@CIT0030]\] in China reported that serum vitamin B~12~ concentration was lower in 84 NTD-affected pregnant women than in 110 controls (*P*\<0.01). Furthermore a recent study reported that deficient or inadequate maternal vitamin B~12~ status is associated with a significantly increased risk for neural tube defects\[[@CIT0031]\]. According to findings of our study serum homocysteine concentration was not significant between cases and controls, but Mills\[[@CIT0032]\] reported that mothers of children with neural-tube defects had significantly higher homocysteine values (8.62 \[SD 2.8\] micromole/ lit).

Also Ratan study\[[@CIT0033]\] showed that high plasma homocysteine in both parents had an association with NTD. Ratan concluded that NTD may not only be due to nutritional deficiency in the mothers but also due to more intricate gene-nutrient interaction defects in the affected families, probably some abnormal folate-homocysteine metabolism.

These variations in different studies could be explained by the influence of racial, ethnic and socioeconomic, geographical, nutritional and biological factors in various parts of the world. Other reasons for these variations in the differences are the sample size and time of sampling.

Despite about two decades past the administration of folic acid in reproductive age women and in programmed pregnancy by the health system, some factors such as low doses of consumption, gastrointestinal disorders and lack of knowledge about the importance of folic acid in normal development of fetus can affect the success of this important program.

However, this study has certain limitations. Firstly the sample size was small. Secondly, we are not aware how many cases or controls were taking folic acid or B~12~--containing supplements periconceptionally (ie, before and after conception).

Conclusion {#S0005}
==========

This study showed that maternal folate deficiency can increase the probability of a fetus to have NTDs as compared to pregnancies with normal folate. In our opinion, folate supplements are appropriate to prevent recurrence of NTD in infants of high--risk women. Finding of lower folate levels in case mothers than in control mothers would have supported the use of folate supplements to prevent NTDs in low-risk populations. This finding focuses attention to the importance of nutritional factors in addition to genetic role in the etiology of neural tube defects. Further studies should be carried out with large sample size to verify the cause-effect relationship of homocysteine metabolism with NTD.
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